Central vision can fade slowly with age-related macular degeneration. Faces blur. Words smear on a page. A dark spot can sit ...

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, is pleased to announce the ...

Scientists at USC are launching a new trial to test a tiny stem cell implant that could restore vision in people with advanced dry macular degeneration. The hair-thin patch replaces damaged retinal ...

Age-related macular degeneration (AMD) once meant a slow, irreversible loss of vision, and many people still believe that's true. But the AMD of today isn't the AMD of ...

Companies across the globe are diligently working toward developing novel Dry Age Macular Degeneration treatment therapies ...

Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...

An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation's PRIMA implant is the first treatment in clinical trials to successfully restore functional ...

PulseSight Therapeutics completes patient enrolment in phase I trial of PST-611 to treat dry AMD/geographic atrophy: Paris, France Friday, January 23, 2026, 18:00 Hrs [IST] PulseS ...

The Phase 2b SIGLEC study comparing the safety and efficacy of three GA treatments—high-dose AVD-104, low-dose AVD-104, and avacincaptad pegol—has enrolled approximately 100 patients in each study arm ...

Medically reviewed by Christine L. Larsen, MD Key Takeaways Macular degeneration is a common eye disease, affecting more than 19 million people in the United States alone.The condition can reduce a ...

Macular degeneration (MD) is characterised by the progressive breakdown of the macula, the portion of the retina responsible for sharp, central vision, leading to visual distortion or loss.